255 related articles for article (PubMed ID: 31472940)
1. TCGA molecular groups of endometrial cancer: Pooled data about prognosis.
Raffone A; Travaglino A; Mascolo M; Carbone L; Guida M; Insabato L; Zullo F
Gynecol Oncol; 2019 Nov; 155(2):374-383. PubMed ID: 31472940
[TBL] [Abstract][Full Text] [Related]
2. Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups.
Travaglino A; Raffone A; Stradella C; Esposito R; Moretta P; Gallo C; Orlandi G; Insabato L; Zullo F
Arch Gynecol Obstet; 2020 Jun; 301(6):1355-1363. PubMed ID: 32296930
[TBL] [Abstract][Full Text] [Related]
3. Classification of high-grade endometrium carcinomas using molecular and immunohistochemical methods.
Bayramoglu D; Seçilmiş Kerimoğlu Ö; Bayramoğlu Z; Çintesun E; Şahin G; Karabağlı P; Çelik Ç
Ginekol Pol; 2023; 94(1):3-11. PubMed ID: 35072228
[TBL] [Abstract][Full Text] [Related]
4. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients.
Wu Q; Zhang N; Xie X
BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827
[TBL] [Abstract][Full Text] [Related]
5. TCGA Molecular Subgroups in Endometrial Undifferentiated/Dedifferentiated Carcinoma.
Travaglino A; Raffone A; Mascolo M; Guida M; Insabato L; Zannoni GF; Zullo F
Pathol Oncol Res; 2020 Jul; 26(3):1411-1416. PubMed ID: 31811476
[TBL] [Abstract][Full Text] [Related]
6. TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma.
Travaglino A; Raffone A; Gencarelli A; Mollo A; Guida M; Insabato L; Santoro A; Zannoni GF; Zullo F
Pathol Oncol Res; 2020 Oct; 26(4):2067-2073. PubMed ID: 32472441
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma.
Raffone A; Travaglino A; Raimondo D; Neola D; Renzulli F; Santoro A; Insabato L; Casadio P; Zannoni GF; Zullo F; Mollo A; Seracchioli R
Gynecol Oncol; 2021 Aug; 162(2):401-406. PubMed ID: 34088515
[TBL] [Abstract][Full Text] [Related]
8. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
[TBL] [Abstract][Full Text] [Related]
9. TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma.
Travaglino A; Raffone A; Mollo A; Borrelli G; Alfano P; Zannoni GF; Insabato L; Zullo F
Arch Gynecol Obstet; 2020 May; 301(5):1117-1125. PubMed ID: 32253551
[TBL] [Abstract][Full Text] [Related]
10. Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis.
McConechy MK; Talhouk A; Leung S; Chiu D; Yang W; Senz J; Reha-Krantz LJ; Lee CH; Huntsman DG; Gilks CB; McAlpine JN
Clin Cancer Res; 2016 Jun; 22(12):2865-73. PubMed ID: 26763250
[TBL] [Abstract][Full Text] [Related]
11. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
[TBL] [Abstract][Full Text] [Related]
12. [Application and clinical significance of TCGA molecular classification in endometrial cancer].
Zhao LY; Dai YB; Li LW; Wang ZQ; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2021 Oct; 56(10):697-704. PubMed ID: 34823319
[No Abstract] [Full Text] [Related]
13. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.
Raffone A; Travaglino A; Gabrielli O; Micheli M; Zuccalà V; Bitonti G; Camastra C; Gargiulo V; Insabato L; Zullo F
Arch Gynecol Obstet; 2021 Jun; 303(6):1393-1400. PubMed ID: 33754186
[TBL] [Abstract][Full Text] [Related]
14. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
15. Histopathological characterization of ProMisE molecular groups of endometrial cancer.
Raffone A; Travaglino A; Mascolo M; Carotenuto C; Guida M; Mollo A; Insabato L; Zullo F
Gynecol Oncol; 2020 Apr; 157(1):252-259. PubMed ID: 31932106
[TBL] [Abstract][Full Text] [Related]
16. Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis.
Travaglino A; Raffone A; Santoro A; Raimondo D; Angelico G; Valente M; Arciuolo D; Scaglione G; D'alessandris N; Casadio P; Inzani F; Mollo A; Seracchioli R; Zannoni GF
Gynecol Oncol; 2021 Sep; 162(3):804-808. PubMed ID: 34266691
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
[TBL] [Abstract][Full Text] [Related]
18. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Zighelboim I; Ali S; Lankes HA; Backes F; Moore K; Mutch D; Robison K; Behbakht K; Waggoner S; Ghebre RG; Pearl M; Ramirez NC; Goodfellow P
Gynecol Oncol; 2015 Sep; 138(3):614-9. PubMed ID: 26144601
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability as a marker of prognosis: a systematic review and meta-analysis of endometrioid endometrial cancer survival data.
Xiao JP; Wang JS; Zhao YY; Du J; Wang YZ
Arch Gynecol Obstet; 2023 Feb; 307(2):573-582. PubMed ID: 35665848
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG).
Mackay HJ; Gallinger S; Tsao MS; McLachlin CM; Tu D; Keiser K; Eisenhauer EA; Oza AM
Eur J Cancer; 2010 May; 46(8):1365-73. PubMed ID: 20304627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]